News

  • 26 September 2011

    Acetylon begins Phase I/IIa trial of ACY-1215 drug

    Acetylon Pharmaceuticals has initiated a Phase I/IIa clinical trial of ACY-1215, an oral Class II histone deacetylase inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

  • 22 September 2011

    Merck opens Irish R&D facility

    US-based pharmaceutical major Merck has opened a €100m R&D facility at Ballydine, Co Tipperary, Ireland.

  • 21 September 2011

    Sanofi to enter lucrative acne market

    France-based pharmaceutical major Sanofi has acquired the rights to an investigational acne treatment, signalling a move into the lucrative market.

  • 21 September 2011

    Johnson & Johnson resumes Tylenol shipments

    Johnson & Johnson has resumed shipping its Tylenol Cold and Flu Severe caplets, made by McNeil Consumer Healthcare, more than a year after the product was recalled due to manufacturing...

  • 20 September 2011

    BARDA funds Vaxin to develop anthrax vaccine

    Vaxin, a clinical-stage vaccine development company, has been awarded a $21.7m contract by the Office of Biomedical Advanced Research and Development Authority (BARDA) for the development of the company's proprietary...

Go Top